Biotech Values

[biocqr]

FGEN > Esbriet stops working at 1 yr in IPF....

Esbriet’s Efficacy in Severe IPF Seen to Diminish 6-12 Months After Treatment’s Start, Study Shows

https://pulmonaryfibrosisnews.com/2017/11/08/in-severe-ipf-esbriet-no-longer-effective-after-one-year-of-treatment-greek-study-shows/?utm_source=Pulmonary+Fibrosis&utm_campaign=c2b2db8ce8-RSS_MONDAY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_3c2b971ae5-c2b2db8ce8-72358917

Patients who had been treated with Esbriet before or showed significant comorbidities such as cancer, liver failure or renal failure were excluded from the study.

The team analyzed the results of 34 males and nine females with severe lung function impairment who received Esbriet (2.403 mg/daily) for between six months and one year. Patients’ mean age was 66.3 years, and most were ex-smokers.

The analysis showed that Esbriet administered for six months was associated with a trend for halting functional decline when compared to patients’ lung function in the six months before beginning treatment. These effects appear to then start diminishing.

“However, pirfenidone failed to show any benefit or even halt disease progression after one year of treatment,” the researchers wrote.